BridgeBio Pharma Share Holder Equity 2018-2024 | BBIO
BridgeBio Pharma share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
BridgeBio Pharma Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$-1,343 |
| 2022 |
$-1,243 |
| 2021 |
$-867 |
| 2020 |
$106 |
| 2019 |
$474 |
| 2018 |
$377 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$-1,082 |
| 2024-03-31 |
$-1,037 |
| 2023-12-31 |
$-1,343 |
| 2023-09-30 |
$-1,195 |
| 2023-06-30 |
$-1,350 |
| 2023-03-31 |
$-1,213 |
| 2022-12-31 |
$-1,243 |
| 2022-09-30 |
$-1,128 |
| 2022-06-30 |
$-1,014 |
| 2022-03-31 |
$-1,041 |
| 2021-12-31 |
$-867 |
| 2021-09-30 |
$-739 |
| 2021-06-30 |
$-457 |
| 2021-03-31 |
$-389 |
| 2020-12-31 |
$106 |
| 2020-09-30 |
$216 |
| 2020-06-30 |
$326 |
| 2020-03-31 |
$449 |
| 2019-12-31 |
$474 |
| 2019-09-30 |
$522 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
